ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) are overexpressed in osteosarcoma.
• ZD6474 is a small molecule inhibitor targeting VEGFR and EGFR tyrosine kinases, showing potential in various cancers.
• Celecoxib is a selective COX-2 inhibitor.

Purpose of the Study:

• To investigate the anti-osteosarcoma effects of ZD6474, alone and in combination with celecoxib.
• To explore the underlying molecular mechanisms of ZD6474's action and the synergistic effect of the combination therapy.

Main Methods:

• In vitro studies on osteosarcoma cell lines assessing cell growth, cell cycle, and apoptosis.
• In vivo studies using nude mice xenograft models to evaluate tumor growth inhibition.
• Western blot analysis to examine protein expression and pathway activation (PI3k/Akt, MAPK/ERK).

Main Results:

• ZD6474 inhibited osteosarcoma cell growth, induced G1-phase arrest, and promoted apoptosis by suppressing EGFR tyrosine kinase activity and downstream PI3k/Akt and MAPK/ERK pathways.
• ZD6474 demonstrated dose-dependent tumor growth inhibition in vivo.
• Celecoxib also showed dose-dependent inhibition of osteosarcoma growth.
• The combination of ZD6474 and celecoxib exhibited synergistic or additive anti-tumor effects both in vitro and in vivo.
• ZD6474 downregulated COX-2 expression via ERK inhibition, while celecoxib enhanced ZD6474's ERK inhibition, potentially explaining the synergism.

Conclusions:

• ZD6474 possesses direct anti-proliferative activity against osteosarcoma cells.
• The combination of ZD6474 and celecoxib demonstrates significant synergistic anti-tumor effects.
• This combination therapy represents a potential novel strategy for treating human osteosarcoma.